Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Abstract Background A new estrogen-free contraceptive has been approved by both the FDA and more than 15 European authorities. It is composed of drospirenone (DRSP) at a dosage of 4 mg in a regimen 24/4. The molecule is known to have anti-gonadotropic, anti-mineralocorticoid, anti-estrogenic, and antiandrogenic properties.
Authors Authors and affiliations D.L. Kendler H.G. Bone F. Massari E. Gielen S. Palacios J. Maddox C. Yan S. Yue R.V. Dinavahi C. Libanati A. Grauer Open Access Original Article First Online: 18 October 2019 Abstract Summary Romosozumab is a therapy that stimulates bone formation and reduces bone resorption.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.